Transaction overview

Ascension, a leading non-profit health system in the United States, acquired AMSURG on June 5, 2026. The details of the deal value are undisclosed, but it involves a 100% stake acquisition. AMSURG is a national leader in developing, managing, and operating ambulatory surgery centers (ASCs), with over 300 ASCs across multiple states.

Deal structure and financing

The specific terms of the deal's equity and debt components are not disclosed publicly. Milbank LLP served as legal counsel to AMSURG on this acquisition but no information is available regarding the lead banks or other financial advisors involved in structuring the transaction. As a result, leverage metrics and any retained stake by the seller remain unknown at this time. There is also no clarity on whether there are lock-up provisions that prevent AMSURG's former shareholders from selling their shares for a period following the acquisition.

Strategic context

Ascension sought to expand its reach into community-based care settings through this transaction, which aligns with broader trends in healthcare shifting towards outpatient services and reducing reliance on hospital infrastructure. For AMSURG, the rationale behind divestiture may involve strategic alignment or financial incentives from Ascension. This deal builds upon Ascension's existing portfolio of ambulatory surgery centers, further solidifying its position as a major player in this sector of community health care provision.

Regulatory path

Given the substantial size and cross-jurisdictional nature of the transaction involving healthcare providers, it is likely that federal antitrust authorities such as the Federal Trade Commission (FTC) or Department of Justice (DOJ) reviewed the deal. Ascension operates across multiple states, so state-level regulatory scrutiny may also have been required in key markets where AMSURG's centers are located. No specific details on remedies imposed or timeline for clearance have emerged publicly at this stage.